Diagnosis & Disease Information

Investigators compared clinical outcomes between unfit patients with newly diagnosed AML who were treated with either azacitidine or decitabine.

For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.

Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.

Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.

Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.